Lab Reference• 7 min read
BPC-157 Dosage & Research Protocols (Laboratory Reference)
This is a laboratory-reference summary of how BPC-157 is dosed across the published preclinical literature. It is not medical or dosing advice — BPC-157 is not approved by the FDA for human use.
Standard reconstitution
A 5 mg vial reconstituted with 2.5 mL bacteriostatic water yields 2 mg/mL. A 10 mg vial reconstituted with 2 mL yields 5 mg/mL. Both are common starting concentrations for in-vivo research administrations on insulin syringes.
Dosing in the literature
- Sikiric group rat models: 10 µg/kg and 10 ng/kg both produce comparable healing effects in tendon, ligament, and GI models
- Intraperitoneal, subcutaneous, and oral routes all appear in the literature with broadly comparable outcomes — BPC-157 is acid-stable
- Most protocols dose once or twice daily across a 1–4 week study window
Why some sources cite mg-range doses
Internet protocols often quote 250–500 µg per administration. These are extrapolations from rodent µg/kg numbers scaled to human body mass and are not derived from controlled clinical trials. Treat them as research-design reference points, not validated dosing.
Route considerations in published models
- Subcutaneous — most common in soft-tissue injury studies; convenient for repeated administration
- Intraperitoneal — common in rodent vascular and inflammation studies
- Oral / drinking water — used in GI-protection and IBD models (BPC-157 survives stomach acid)